AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00868283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Description: 30 ml will be given once daily by intravenous infusion for 10 consecutive days.
Study NCT01622881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
Study NCT01622881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
Study NCT02971670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rTSST-1 Variant Candidate Vaccine
Description: Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
Study NCT02971670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTSST-1 Variant Candidate Vaccine
Description: Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
Study NCT02895061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: Alfacalcidol 1 microgram/capsule
Study NCT01665118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trusculpt (Radio Frequency) Device
Study NCT03250403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: peri-neural injection of platelet rich plasma
Study NCT03250403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional medical treatment
Description: traditional medical treatment
Study NCT03250403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional medical treatment
Description: traditional medical treatment
Study NCT00884104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Oral
Study NCT02224378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peep induced CVP
Study NCT02224378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: passive leg raising(PLR)
Study NCT02772861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement - One dose
Description: 20gr
Study NCT02772861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid Supplement - One dose
Description: 20gr
Study NCT02772861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-Methylhistidine
Description: 120mgr
Study NCT00237003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational interviewing
Description: Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
Study NCT04697498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral bi-level Erector spine plane block
Description: After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
Study NCT04697498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: The control group - will include patients who will undergo surgery under general anaesthesia
Study NCT02844114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum spore
Description: G 300mg, 5 tablets by mouth
Study NCT02844114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic tramadol 1500mg tablet
Study NCT03223233 — intervention group
Intervention type: OTHER
Intervention: procalcitonin level
Description: serum procalcitonin level will be measured in both groups.
Study NCT02844114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: iv.30 minutes
Study NCT02844114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: iv.30 minutes
Study NCT02303548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Administer Sodium bicarbonate 50 mEq IV over 2 minutes
Study NCT02303548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT04119349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra counseling
Description: Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
Study NCT01861210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Voluntary HIV Counseling and Testing
Study NCT01861210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Counseling and Testing
Study NCT04842162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: indocyanine green (INFRACYANINE© 25mg/10mL).
Study NCT03362437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Form A
Study NCT03362437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Form B
Study NCT01822600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels \< 25 g/L.
Study NCT01822600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up.
Study NCT03429192 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgeries plus dissection of lymph nodes
Study NCT01926548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ Imatinib mesylate tablet
Study NCT01926548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gleevec film-coated tablet 2 x 100mg
Study NCT02435225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction for Teens Group
Description: A 12-Week weekly group intervention to train adolescents in mindfulness practice
Study NCT02456779 — intervention group
Intervention type: OTHER
Intervention: in vitro diagnostic test (Peptest)
Description: saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
Study NCT02456779 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: all recruited subjects to complete the RDQ as a determinant of inclusion criteria
Study NCT00866138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: masitinib 9 mg/kg/day per os
Study NCT03353857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel/ Microlut
Description: In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26
Study NCT03353857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/ Noriday
Description: In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
Study NCT03353857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel/ Cerazette
Description: In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26
Study NCT03353857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest/ Visanne
Description: In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26
Study NCT03353857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone, Ethinylestradiol/ Yasmin
Description: In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
Study NCT03353857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam/ Midazolam-ratiopharm
Description: In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26
Study NCT03353857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day
Study NCT01325428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib once daily (OD)
Description: Patient to receive afatinib monotherapy until progression of their disease
Study NCT01325428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Weekly
Description: Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
Study NCT00892632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP and Confocal imaging
Description: A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
Study NCT00725075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8435 (Org 25935) 4-8 mg
Description: Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
Study NCT00725075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for MK-8435 (Org 25935) administered orally BID
Study NCT00725075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8435 (Org 25935) 12-16 mg
Description: Administered orally BID for a final concentration of 24-32 mg/day
Study NCT00876135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ventolin
Description: Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
Study NCT05749380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AmBisome
Description: Reference, dose of 3 mg/kg.
Study NCT05749380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DKF-5122
Description: Test, dose of 3 mg/kg
Study NCT03713944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC 5
Study NCT03713944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2
Study NCT03713944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200mg
Study NCT03713944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg
Study NCT02184871 — intervention group
Intervention type: OTHER
Intervention: exposure to different risk factors and molecular assessment
Study NCT02090400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bazedoxifene
Description: 20 mg Oral daily for 12 months
Study NCT02090400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Calcium/Vit D
Description: Calcium 500 mg / 400 IU Vit D
Study NCT01975012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available.
Study NCT01908660 — intervention group
Intervention type: DRUG
Intervention: antiretroviral drugs
Description: zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
Study NCT00280007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
Study NCT00280007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
Study NCT01278498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: first week:5mg 2nd week\~12 week:10mg
Study NCT01278498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: first week:5mg 2nd week\~12 weeks:10mg
Study NCT02223572 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hip Xray
Study NCT04017143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV app intervention
Description: Participants assigned to this group will receive an HPV app that targets a dyad of parent and a teen boy or girl.
Study NCT03227705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometrium
Description: Intravaginal use, off label, of Prometrium
Study NCT03227705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prometrium
Description: Intravaginal use, off label, of Prometrium
Study NCT03227705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Arabin, cerclage pessary perforated
Description: A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
Study NCT01309178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
Study NCT01309178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannite
Description: Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
Study NCT04063371 — intervention group
Intervention type: OTHER
Intervention: Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)
Description: The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.
Study NCT04063371 — intervention group
Intervention type: OTHER
Intervention: Informant Conversation
Description: If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
Study NCT01024998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 2 x 10\^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
Study NCT01024998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 2 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
Study NCT01024998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 6 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
Study NCT01024998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 2 x 10\^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
Study NCT03993184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hot Yoga
Description: Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
Study NCT03039842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Study NCT03039842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study NCT03039842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan+memantine
Study NCT03039842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+valproate
Study NCT03609307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intravitreal bevacizumab and propranolol
Description: these patients receive two injections at each session Bavacizumab and propranolol
Study NCT03609307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab
Description: these patients receive only Bevacizumab
Study NCT02698488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphology
Study NCT02698488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphology and Mass Spectroscopy
Study NCT03505229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
Study NCT03493217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: The drug product is a white, round, uncoated tablet.
Study NCT02333617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point \[No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)\]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
Study NCT02333617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization
Description: Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
Study NCT02333617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.